ESMO Events 2025

Meetings abre em uma nova guia/janela | ESMO abre em uma nova guia/janela

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO Gastrointestinal Cancers Congress 2025 abre em uma nova guia/janela

This important event will bring together leading experts, researchers, and healthcare professionals dedicated to the advancement of gastrointestinal cancers treatment and care.

Through groundbreaking presentations, multidisciplinary tumour boards, controversy sessions, and more, attendees will have the opportunity to delve into the latest research findings, innovative therapeutic strategies, and emerging technologies that are shaping the future of GI cancers treatment.

The programme will cover a wide spectrum of topics, including molecular prevention, diagnosis, precision therapy, and patient-centered care approaches in the treatment of GI malignancies.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population☆ abre em uma nova guia/janela J.F. Seligmann, D. Morton, F. Elliott, K. Handley, R. Gray, M. Seymour, B. Glimelius, L. Magill, C.J.M. Williams, P. Quirke, D. Bottomley, H.M. Wood, K. Murakami, A.D. Beggs, N.P. West on behalf of the FOxTROT Collaborative Group

• The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study abre em uma nova guia/janela E. Rangelova, T.F. Stoop, T.M.E. van Ramshorst, M. Ali, E.A. van Bodegraven, A.A. Javed, D. Hashimoto, E. Steyerberg, A. Banerjee, A. Jain, A. Sauvanet, A. Serrablo, A. Giani, A. Giardino, A. Zerbi, A. Arshad, A.G. Wijma, A. Coratti, A. Zironda, A. Socratous, A. Rojas, A. Halimi, A. Ejaz, A. Oba, B.Y. Patel, B. Björnsson, B.N. Reames, B. Tingstedt, B.K.P. Goh, C. Payá-Llorente, C.D. Del Pozo, C. González-Abós, C. Medin, C.H.J. van Eijck, C. de Ponthaud, C. Takishita, C. Schwabl, C. Månsson, C. Ricci, C.A. Thiels, D. Douchi, D.L. Hughes, D. Kilburn, D. Flanking, D. Kleive, D.S. Silva, B.H. Edil, E. Pando, E. Moltzer, E.F. Kauffman, E. Warren, E. Bozkurt, E. Sparrelid, E. Thoma, E. Verkolf, F. Ausania, F. Giannone, F.J. Hüttner, F. Burdio, F.R. Souche, F. Berrevoet, F. Daams, F. Motoi, G. Saliba, G. Kazemier, G. Roeyen, G. Nappo, G. Butturini, G. Ferrari, G. Kito Fusai, G. Honda, G. Sergeant, H. Karteszi, H. Takami, H. Suto, I. Matsumoto, I. Mora-Oliver, I. Frigerio, J.M. Fabre, J. Chen, J.G. Sham, J. Davide, J. Urdzik, J. de Martino, K. Nielsen, K. Okano, K. Kamei, K. Okada, K. Tanaka, K.J. Labori, K.E. Goodsell, L. Alberici, L. Webber, L. Kirkov, L. de Franco, M. Miyashita, M. Maglione, M. Gramellini, M. Ramera, M.J. Amaral, M. Ramaekers, M.J. Truty, M.A. van Dam, M.W.J. Stommel, M. Petrikowski, M. Imamura, M. Hayashi, M. D’Hondt, M. Brunner, M.E. Hogg, C. Zhang, M.Á. Suárez-Muñoz, M.D. Luyer, M. Unno, M. Mizuma, M. Janot, M.A. Sahakyan, N.B. Jamieson, O.R. Busch, O. Bilge, O. Belyaev, O. Franklin, P. Sánchez-Velázquez, P. Pessaux, P.S. Holka, P. Ghorbani, R. Casadei, R. Sartoris, R.D. Schulick, R. Grützmann, R. Sutcliffe, R. Mata, R.B. Patel, R. Takahashi, S. Rodriguez Franco, S.S. Cabús, S. Hirano, S. Gaujoux, S. Festen, S. Kozono, S.K. Maithel, S.M. Chai, S. Yamaki, S. van Laarhoven, J.S.D. Mieog, T. Murakami, T. Codjia, T. Sumiyoshi, T.M. Karsten, T. Nakamura, T. Sugawara, U. Boggi, V. Hartman, V.E. de Meijer, W. Bartholomä, W. Kwon, Y.X. Koh, Y. Cho, Y. Takeyama, Y. Inoue, Y. Nagakawa, Y. Kawamoto, Y. Ome, Z. Soonawalla, K. Uemura, C.L. Wolfgang, J.Y. Jang, R. Padbury, S. Satoi, W. Messersmith, J.W. Wilmink, M. Abu Hilal, M.G. Besselink, M. Del Chiaro, for the European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS) the International Consortium on Advanced Pancreatic Surgery

• Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials abre em uma nova guia/janela H. Williams, E. Fokas, M. Diefenhardt, C. Lee, F.S. Verheij, D.M. Omer, S.T. Lin, R.F. Dunne, J. Marcet, P. Cataldo, B. Polite, P. Piso, B. Polat, H. Dapper, M. Ghadimi, R.D. Hofheinz, L.-X. Qin, L.B. Saltz, A.J. Wu, M.J. Gollub, J.J. Smith, M.R. Weiser, C. Rödel, J. Garcia-Aguilar, on behalf of the German Rectal Cancer Study Group and the OPRA Consortium

ESMO Open

• Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer abre em uma nova guia/janela D. Mahalingam, A. Saeed, S.F. Powell, M. Huerta, V. Sahai, A.L. Coveler, E.J. Davis, N. Steeghs, M. Mulcahy, A.G. Raufi, L. Cavalcante, A. Cervantes, J. Berlin, T. Weisskittel, A. Ugolkov, A.P. Mazar, W. Mikrut, S. Smith, F.J. Giles, B.A. Carneiro

• Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma abre em uma nova guia/janela R.S. Finn, M. Kudo, P. Merle, T. Meyer, S. Qin, M. Ikeda, R. Xu, J. Edeline, B.-Y. Ryoo, Z. Ren, A.-L. Cheng, P.R. Galle, S. Kaneko, H. Kumada, S. Kamble, J.M. Norquist, K. Mody, A. Wang, L. Dubrovsky, J.M. Llovet

• Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy abre em uma nova guia/janela G. Sharma, Y. Baca, A.F. Shields, A. Prakash, B.A. Weinberg, A. Saeed, S. Goel, A. Abdalla, M. Oberley, J. Xiu, J. Hwang, E.S. Antonarakis, V.K. Chiu, E. Lou

Immuno-Oncology and Technology

• A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE) abre em uma nova guia/janela I.M. Chen, S. Theile, K. Madsen, J.S. Johansen, T. Lorentzen, A. Toxværd, E. Høgdall, I.M. Svane, D. Nielsen

• Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics abre em uma nova guia/janela B.E. Nelson, A. Naing, S. Fu, R.A. Sheth, R. Murthy, S. Piha-Paul

ESMO Gastrointestinal Oncology

• Genomic heterogeneity and clinical implications in gastrointestinal neuroendocrine carcinoma: MYC and KRAS as predictive biomarkers abre em uma nova guia/janela T. Ozato, Y. Kono, H. Yamamoto, A. Hirasawa, D. Ennishi, S. Tomida, S. Toyooka, M. Otsuka

• Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma abre em uma nova guia/janela S. Shim, A.C. Larsen, L. Bæksgaard, P. Pfeiffer, M. Nordsmark, J.R. Sørensen, A.K. Motavaf, M. Ladekarl

• Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma abre em uma nova guia/janelaJ.W. Valle, G.K. Abou-Alfa, R.K. Kelley, M.A. Lowery, R.T. Shroff, Y. Bian, G. Saint-Hilary, H. Liu, Z. Teng, Z. Hua, C. Gliser, A. Vogel, M.M. Javle

ESMO Real World Data and Digital Oncology

• Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry☆ abre em uma nova guia/janela K. Potthoff, H. Bläker, T. Dechow, A. Binninger, K. Ringwald, R. de Buhr, E. von der Heyde, M.-O. Zahn, A. Nusch, S. Dörfel, H. Schulz, I. Haffner, A.K. Höhn, A. Monecke, S. Lorenzen, A. Reinacher-Schick, M. Jänicke, F. Lordick

• Real-world treatment patterns and survival in patients with synchronous and metachronous metastatic colorectal cancer in the Netherlands abre em uma nova guia/janela M.A.G. Elferink, F.N. van Erning, F.C. Sijtsma, L.B. Valkenburg-van Iersel, M.L. Wumkes, J.M.L. Roodhart, G.R. Vink

• Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort abre em uma nova guia/janela G. George, M. Rowley, A.C.C. Coolen, A. Santa Olalla, N. Hammar, M. Feychting, S.N. Karagiannis, D. Enting, M. Van Hemelrijck

ESMO affiliated journals

• EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases abre em uma nova guia/janela Giacomo Bregni, Richard Adams, Reto Bale, Maria A Bali, Irene Bargellini, Lennart Blomqvist, Gina Brown, Chiara Cremolini, Pieter Demetter, Timm Denecke, Anthony Dohan, Cristina Dopazo, Elena Elez, Serge Evrard, Roger Feakins, Matthias Guckenberger, Marianne Gronlie Guren, Maria Hawkins, Anne Hoorens, Emmanuel Huguet, Martijn Intven, Thibaud Koessler, Wolfgang G Kunz, Florian Lordick, Valerio Lucidi, Andreas H Mahnken, Hassan Malik, Philippe Martinive, Murielle Mauer, Alejandra Méndez Romero, Iris Nagtegaal, Franco Orsi, Wim JG Oyen, Olivier Pellerin, Marco Rengo, Jens Ricke, Alexis Ricoeur, Angela Riddell, Maxime Ronot, Marta Scorsetti, Jenny Seligmann, Christine Sempoux, Kieran Sheahan, Stefan Stättner, Magali Svrcek, Julien Taieb, Nick West, Lucjan Wyrwicz, Christoph J Zech, Markus Moehler, Francesco Sclafani

• The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers abre em uma nova guia/janela Giuseppe Cabibbo, Lorenza Rimassa, Angela Lamarca, Gianluca Masi, Bruno Daniele, David James Pinato, Andrea Casadei-Gardini

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.